anti-CD20 humanized monoclonal antibody (Tianjin Bofa Biotechnology)

N/A

Report date: 2025/01/26 18:22:09

Base Information

Drug Nameanti-CD20 humanized monoclonal antibody (Tianjin Bofa Biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTianjin Bogene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Bogene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A